MedTrace Logo

Special Access Program IMVAMUNE®

NCT03472014 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2020-08-19

Study results available
· View outcomes & findings →

Summary

Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of replicating vaccinia virus

Conditions

  • Vaccination

Interventions

BIOLOGICAL

IMVAMUNE®

IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose

Sponsors & Collaborators

  • Bavarian Nordic

    lead INDUSTRY

Principal Investigators

  • Gary Fujimoto, MD · Palo Alto Medical Foundation

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-22
Primary Completion
2014-11-14
Completion
2014-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03472014 on ClinicalTrials.gov